BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 524 filers reported holding BIO-TECHNE CORP in Q3 2022. The put-call ratio across all filers is 0.22 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $838,486 | -14.3% | 12,318 | +2.8% | 0.01% | -16.7% |
Q2 2023 | $978,499 | -75.1% | 11,987 | -77.4% | 0.01% | -75.0% |
Q1 2023 | $3,931,031 | +740.2% | 52,986 | +838.6% | 0.02% | +700.0% |
Q4 2022 | $467,858 | -58.4% | 5,645 | +42.5% | 0.00% | -50.0% |
Q3 2022 | $1,125,000 | -30.7% | 3,962 | -15.4% | 0.01% | -14.3% |
Q2 2022 | $1,623,000 | +4.3% | 4,681 | +30.3% | 0.01% | +16.7% |
Q1 2022 | $1,556,000 | +191.4% | 3,593 | +248.2% | 0.01% | +100.0% |
Q4 2021 | $534,000 | +14.8% | 1,032 | +7.5% | 0.00% | 0.0% |
Q3 2021 | $465,000 | +12.6% | 960 | -54.5% | 0.00% | -25.0% |
Q3 2019 | $413,000 | -76.7% | 2,110 | -82.8% | 0.00% | -75.0% |
Q4 2018 | $1,775,000 | +349.4% | 12,267 | +534.6% | 0.02% | +300.0% |
Q3 2018 | $395,000 | -65.0% | 1,933 | -74.7% | 0.00% | -63.6% |
Q2 2018 | $1,130,000 | -12.7% | 7,636 | -10.9% | 0.01% | -8.3% |
Q1 2018 | $1,294,000 | +448.3% | 8,567 | +338.2% | 0.01% | +500.0% |
Q3 2017 | $236,000 | -58.8% | 1,955 | -59.9% | 0.00% | -60.0% |
Q2 2017 | $573,000 | +157.0% | 4,878 | +96.9% | 0.01% | +66.7% |
Q4 2015 | $223,000 | -81.4% | 2,478 | -80.9% | 0.00% | -81.2% |
Q3 2015 | $1,200,000 | +179.7% | 12,978 | +203.1% | 0.02% | +433.3% |
Q1 2015 | $429,000 | +16.6% | 4,282 | +7.5% | 0.00% | 0.0% |
Q4 2014 | $368,000 | – | 3,982 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Broadcrest Asset Management, LLC | 300,000 | $24,489,000 | 21.05% |
Montanaro Asset Management Ltd | 388,800 | $31,737,744 | 5.02% |
Sandhill Capital Partners LLC | 502,447 | $41,014,775 | 3.74% |
Brown Capital Management | 3,160,892 | $258,023,614 | 3.66% |
DF DENT & CO INC | 3,275,617 | $267,388,640 | 3.62% |
Ownership Capital B.V. | 2,282,104 | $186,288,150 | 3.26% |
Jackson Square Partners, LLC | 1,361,789 | $111,162,836 | 3.24% |
STONE RUN CAPITAL, LLC | 88,135 | $7,194,460 | 3.20% |
Pembroke Management, LTD | 339,591 | $27,720,813 | 2.99% |
Summit Creek Advisors LLC | 283,693 | $23,157,860 | 2.90% |